Stock Events

Stock Events

Sensei Biotherapeutics 

0
27
+€0.00+0% 00:00 Today

Statistics

Day High
-
Day Low
-
52W High
-
52W Low
-
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

10NovExpected
Q1 2026
Q2 2026
Next
-113.07
-75.56
-38.05
-0.53
Expected EPS
-0.68622773688
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
0Revenue
-18.44MNet Income

Analyst Ratings

42.42Average Price Target
The highest estimate is 45.53.
From 11 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
BioNTech
BNTX
Mkt Cap25.64B
BioNTech competes in the immunotherapy space, focusing on personalized cancer vaccines which is similar to Sensei's approach in targeting cancer.
Moderna
MRNA
Mkt Cap55.09B
Moderna is involved in mRNA-based therapies, including cancer vaccines, competing in the same immunotherapy field as Sensei.
Novavax
NVAX
Mkt Cap1.53B
Novavax, though primarily known for its work on vaccines, is exploring cancer vaccine candidates, making it a competitor in the immunotherapy space.
Gilead Sciences
GILD
Mkt Cap180.64B
Gilead Sciences, with its acquisition of Kite Pharma, has a strong presence in the cell therapy and immunotherapy market, directly competing with Sensei's cancer treatment strategies.
AMGEN
AMGN
Mkt Cap233.78B
Amgen has a diverse portfolio in oncology, including immunotherapies, which pits it against Sensei in the race for effective cancer treatments.
Bristol-Myers Squibb
BMY
Mkt Cap136B
Bristol Myers Squibb, with its extensive range of immunotherapy treatments including Opdivo, competes in the same space as Sensei, focusing on innovative cancer therapies.
Merck
MRK
Mkt Cap366B
Merck is a key player in the immunotherapy market with its blockbuster drug Keytruda, making it a direct competitor to Sensei's cancer immunotherapy efforts.
Pfizer
PFE
Mkt Cap159.36B
Pfizer, with its investments in cancer research and immunotherapy, including partnerships for vaccine development, competes in the same arena as Sensei.
Novartis
NVS
Mkt Cap292.35B
Novartis has a strong focus on innovative medicines, including immunotherapies for cancer, making it a competitor in the same field as Sensei.

About

Faeth Therapeutics Inc is a clinical-stage biotechnology company focused on improving outcomes for cancer patients through multi-node inhibition of critical oncogenic pathways. The company's principal program is PIKTOR, an investigational all-oral combination of serabelisib and sapanisertib in development for endometrial and breast cancer.
Show more...
CEO
Anand Parikh
Employees
29
Country
United States
ISIN
US81728A1088

Listings

MU
DE
407.MU
XNAS
US
FTH
F
DE
4070.F
STU
DE
4070.STU

0 Comments

Share your thoughts

FAQ

What is Sensei Biotherapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on Boerse Muenchen exchange Sensei Biotherapeutics stocks are traded under the ticker 407.MU.
When is the next Sensei Biotherapeutics earnings date?▼
Sensei Biotherapeutics is going to release the next earnings report on November 10, 2026.
What were Sensei Biotherapeutics earnings last quarter?▼
407.MU earnings for the last quarter are -2.46 EUR per share, whereas the estimation was -2.29 EUR resulting in a -7.74% surprise. The estimated earnings for the next quarter are N/A EUR per share.
What is Sensei Biotherapeutics revenue for the last year?▼
Sensei Biotherapeutics revenue for the last year amounts to 0 EUR.
What is Sensei Biotherapeutics net income for the last year?▼
407.MU net income for the last year is -18.44M EUR.
How many employees does Sensei Biotherapeutics have?▼
As of September 04, 2026, the company has 29 employees.
In which sector is Sensei Biotherapeutics located?▼
Sensei Biotherapeutics operates in the Health & Wellness sector.
When did Sensei Biotherapeutics complete a stock split?▼
The last stock split for Sensei Biotherapeutics was on June 17, 2025 with a ratio of 1:20.
Where is Sensei Biotherapeutics headquartered?▼
Sensei Biotherapeutics is headquartered in AUSTIN, United States.